Malignant Histiocytic and Dendritic Cell Neoplasm — Variants & evidence

Malignant Histiocytic and Dendritic Cell Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

4 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items (4 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V6001
Dabrafenib/Trametinib Regimen	Histiocytic Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID12769 An 8-year-old girl presented with secondary BRAF V600-mutant histiocytic sarcoma following T-cell acute lymphoblastic leukemia. After the poor response to initial salvage chemotherapy, the patient res… (full text at CIViC) PMID 40057687 · Tan et al., 2025 · Open in CIViC	civic
BRAF V600E1
Vemurafenib	Langerhans Cell Sarcoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID7583 Off-label use of vemurafenib to treat BRAF V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. Fifty-four patients from 12 countries were treated with vem… (full text at CIViC) PMID 31513482 · Donadieu et al., 2019 · Open in CIViC	civic
BRAF V600K1
Dabrafenib/Trametinib Regimen	Histiocytic Sarcoma	Predictive	C	Supports Sensitivity Response	2	rejected	EID12770 An 8-year-old girl presented with secondary BRAF V600-mutant histiocytic sarcoma following T-cell acute lymphoblastic leukemia. After the poor response to initial salvage chemotherapy, the patient res… (full text at CIViC) PMID 40057687 · Tan et al., 2025 · Open in CIViC	civic
BRAF V600R1
Dabrafenib/Trametinib Regimen	Histiocytic Sarcoma	Predictive	C	Supports Sensitivity Response	2	rejected	EID12771 An 8-year-old girl presented with secondary BRAF V600-mutant histiocytic sarcoma following T-cell acute lymphoblastic leukemia. After the poor response to initial salvage chemotherapy, the patient res… (full text at CIViC) PMID 40057687 · Tan et al., 2025 · Open in CIViC	civic

Data updated 13 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.